Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.56 |
| ▸ | CTSS | P25774 | 2/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | CASP1 | P29466 | 9/20 | 0.53 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 3/20 | 0.52 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.51 |
| ▸ | ELANE | P08246 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31264459 | 1.00 | CTSL (0.56) | CTSLCTSSATMCASP1TRPM8 | |
| SCHEMBL3202235 | 0.90 | ATM (0.56) | CTSLCTSSATMCASP1TRPM8 | |
| SCHEMBL19859590 | 0.90 | ATM (0.56) | CTSLCTSSATMCASP1TRPM8 | |
| SCHEMBL9749127 | 0.90 | ATM (0.56) | CTSLCTSSATMCASP1TRPM8 | |
| SCHEMBL25992761 | 0.89 | CTSL (0.54) | CTSLCTSSATMCASP1TRPM8 | |
| SCHEMBL28973696 | 0.89 | CTSL (0.54) | CTSLCTSSATMCASP1TRPM8 | |
| SCHEMBL29400812 | 0.87 | CTSS (0.57) | CTSLCTSSATMTRPM8CTSK | |
| SCHEMBL8353955 | 0.86 | CTSK (0.62) | CTSLCTSSATMTRPM8CTSK | |
| SCHEMBL9383948 | 0.86 | CTSS (0.56) | CTSLCTSSATMTRPM8CTSK | |
| SCHEMBL5197791 | 0.85 | CASP1 (0.52) | CTSLCTSSATMCASP1TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772366-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-10 | — | — | US | disclosed |
| US-20080070953-A1 | Inhibitors of interleukin-1 beta converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070953-A1 | Inhibitors of interleukin-1 beta converting enzyme | IL1B, IL1A, IL1R1 | CTSL 105/4885CTSS 96/4885ATM 4658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.